Detail of "209467-52-7"

Reference

Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia

All Rights Reserved. Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia. Rouse, Mark S.; Hein, Melanie M.; Anguita-Alonso, Paloma; Steckelberg, James M. 88040-23-7 and 209467-52-7 are also occured in this study.; Patel, Robin (Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA). Diagnostic Microbiology and Infectious Disease, 55(4), 333-336 (English) 2006 Elsevier Inc. CODEN: DMIDDZ. ISSN: 0732-8893. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Ceftobiprole (BAL9141) is an investigational cephalosporin active against methicillin- and vancomycin-resistant staphylococci administered as a water-sol. prodrug, ceftobiprole medocaril (BAL5788). Using an immunocompetent murine pneumonia model of Haemophilus influenzae, Enterobacter cloacae, or extended-spectrum b-lactamase (ESBL) nonproducing or producing Klebsiella pneumoniae pneumonia, we compared results of treatment with ceftobiprole medocaril (71 mg/kg, s.c., qid), ceftriaxone (50 mg/kg, i.m., bid), or cefepime (50 mg/kg, i.p., q.i.d.). Results were expressed as median and 25th to 75th percentile log10 colony forming units per g of lung tissue. Ceftobiprole, ceftriaxone, and cefepime were each more active than was no treatment and were equally active for treatment of exptl. H. influenzae, E. cloacae, or ESBL-nonproducing K. pneumoniae pneumonia. For ESBL-producing K. pneumoniae, no differences were detected between no treatment and treatment with ceftobiprole, ceftriaxone, or cefepime. Ceftobiprole is active against H. influenzae, E. cloacae, and ESBL-nonproducing K. pneumoniae in an immunocompetent exptl. murine pneumonia model. .

New agents for Staphylococcus aureus endocarditis

All Rights Reserved. New agents for Staphylococcus aureus endocarditis. Drees, Marci; Boucher, Helen (Tufts-New England Medical Center, Tufts University, Boston, MA, USA). Current Opinion in Infectious Diseases, 19(6), 544-550 (English) 2006 Lippincott Williams & Wilkins. CODEN: COIDE5. ISSN: 0951-7375. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. The increasing prevalence of methicillin-resistant Staphylococcus aureus (MRSA) as well as newly discovered S.There are some reagents with their cas registry numbers 165800-03-3 and 209467-52-7 are used in this study. aureus strains with reduced susceptibility to vancomycin mandates development of new antistaphylococcal agents. Information about currently available and forthcoming antimicrobials for treatment of S. aureus endocarditis is summarized. No new antimicrobial has been proven superior to antistaphylococcal penicillins for treatment of methicillin-sensitive S. aureus (MSSA) endocarditis. Vancomycin has become std. treatment for MRSA but poor outcomes have been reported, both with susceptible and intermediately resistant S. aureus strains (VISA). Linezolid has successfully treated individual cases of MRSA endocarditis, but limitations include long-term safety. Daptomycin has recently been proven effective and well tolerated for MSSA and MRSA bacteremia, including right-sided endocarditis. New glycopeptides, including dalbavancin and telavancin, as well as the new cephalosporin ceftobiprole, have not yet been studied for treatment of endocarditis but appear active against MRSA and potentially VISA. Antistaphylococcal penicillins remain the treatment of choice for MSSA. Of the currently available newer agents, daptomycin appears to have the most rapid bactericidal activity and provides a much-needed alternative to vancomycin for treatment of MRSA or MSSA bacteremia and right-sided endocarditis. .